###begin article-title 0
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
Hyperinsulinism-hyperammonaemia syndrome: novel mutations in the GLUD1 gene and genotype-phenotype correlations
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sirt4</italic>
###xml 179 187 <span type="species:ncbi:9606">Patients</span>
###xml 330 334 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Activating mutations in the GLUD1 gene (which encodes for the intra-mitochondrial enzyme glutamate dehydrogenase, GDH) cause the hyperinsulinism-hyperammonaemia (HI/HA) syndrome. Patients present with HA and leucine-sensitive hypoglycaemia. GDH is regulated by another intra-mitochondrial enzyme sirtuin 4 (SIRT4). Sirt4 knockout mice demonstrate activation of GDH with increased amino acid-stimulated insulin secretion.
###end p 2
###begin title 3
Objectives
###end title 3
###begin p 4
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
To study the genotype-phenotype correlations in patients with GLUD1 mutations. To report the phenotype and functional analysis of a novel mutation (P436L) in the GLUD1 gene associated with the absence of HA.
###end p 4
###begin title 5
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 5
###begin p 6
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT4</italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">Patients</span>
Twenty patients with HI from 16 families had mutational analysis of the GLUD1 gene in view of HA (n=19) or leucine sensitivity (n=1). Patients negative for a GLUD1 mutation had sequence analysis of the SIRT4 gene. Functional analysis of the novel P436L GLUD1 mutation was performed.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 411 416 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 447 452 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT4</italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 128 135 <span type="species:ncbi:9606">patient</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
Heterozygous missense mutations were detected in 15 patients with HI/HA, 2 of which are novel (N410D and D451V). In addition, a patient with a normal serum ammonia concentration (21 mumol/l) was heterozygous for a novel missense mutation P436L. Functional analysis of this mutation confirms that it is associated with a loss of GTP inhibition. Seizure disorder was common (43%) in our cohort of patients with a GLUD1 mutation. No mutations in the SIRT4 gene were identified.
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
Patients with HI due to mutations in the GLUD1 gene may have normal serum ammonia concentrations. Hence, GLUD1 mutational analysis may be indicated in patients with leucine sensitivity; even in the absence of HA. A high frequency of epilepsy (43%) was observed in our patients with GLUD1 mutations.
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 389 392 389 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">(1)</xref>
###xml 476 479 473 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">(2)</xref>
###xml 104 112 <span type="species:ncbi:9606">children</span>
The hyperinsulinism/hyperammonaemia (HI/HA) syndrome is a form of congenital HI (CHI) in which affected children have recurrent symptomatic hypoglycaemia together with a persistently elevated serum ammonia concentration. It has been shown that this disorder is caused by activating mutations in the GLUD1 gene that encodes for the intra-mitochondrial enzyme, glutamate dehydrogenase (GDH) (1). GDH is highly expressed in the liver, pancreatic beta-cells, kidney and the brain (2). It catalyses the oxidative deamination of glutamate to alpha-ketoglutarate and ammonia. In the pancreatic beta-cells, alpha-ketoglutarate enters the tricarboxylic acid cycle and leads to insulin exocytosis.
###end p 12
###begin p 13
###xml 64 67 64 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">(3)</xref>
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 185 188 185 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">(4)</xref>
###xml 449 452 445 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">(5)</xref>
GDH is allosterically activated by leucine and inhibited by GTP (3). Activating mutations in the GLUD1 gene reduce the sensitivity of the enzyme to allosteric inhibition by GTP and ATP (4). The loss of inhibition by GTP leads to increased leucine-induced glutamate oxidation to alpha-ketoglutarate. Hence, leucine sensitivity is manifested by postprandial hypoglycaemia (following protein-rich meals), which is a classical feature of this condition (5). The mechanism of the persistent HA, a striking and consistent feature of this condition, is not completely understood.
###end p 13
###begin p 14
###xml 74 77 74 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">(6)</xref>
###xml 128 134 128 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6 bib7">(6, 7)</xref>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT4</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
GDH is also inhibited by sirtuin 4 (SIRT4), an intra-mitochondrial enzyme (6) that is highly expressed in the pancreatic islets (6, 7). Hence, SIRT4 would be an ideal candidate gene to analyse in patients with HI/HA syndrome, where no mutations in the GLUD1 gene are found.
###end p 14
###begin p 15
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT4</italic>
###xml 437 442 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 131 138 <span type="species:ncbi:9606">patient</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
In this study, we report the phenotype and genotype of 20 patients with HI/HA syndrome. We also report a novel GLUD1 mutation in a patient with severe leucine sensitivity but a completely normal serum ammonia concentration. We highlight the high risk of epilepsy in patients with GLUD1 mutations and we discuss our findings of the SIRT4 gene analysis in a cohort of patients with HI/HA syndrome, where no mutations are identified in the GLUD1 gene.
###end p 15
###begin title 16
Research design and methods
###end title 16
###begin p 17
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 786 793 783 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
We studied 20 patients with HI who were referred for mutational analysis of the GLUD1 gene either in view of HA (n=19) or leucine sensitivity (n=1). Sixteen patients were unrelated and four were related demonstrating vertical transmission of disease consistent with a dominant pattern of inheritance. The diagnosis of HI was based on diagnostic criteria described previously, i.e. inappropriately elevated insulin concentrations at the time of hypoglycaemia with corresponding low concentrations of plasma beta-hydroxybutyrate and fatty acids. Clinical information (birth weight, age of presentation, treatment details, seizure history and family history) was collected from case notes and the referring clinicians. The clinical characteristics are presented as means and summarised in Table 1.
###end p 17
###begin p 18
The study was approved by the regional ethical committee and written consent was obtained from the families.
###end p 18
###begin title 19
Molecular genetics
###end title 19
###begin p 20
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 736 743 736 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
DNA was extracted from peripheral leukocytes using standard procedures. The exons of the GLUD1 gene, which encode the catalytic and allosteric domains of GDH (exons 6, 7, 10, 11 and 12), were amplified by PCR (for primer sequences see Supplementary Table 1, which can be viewed online at ) and sequenced using BigDye Terminator v3.1 (Applied Biosystems, Warrington, UK). Sequencing reactions were analysed on the ABI 3730 (Applied Biosystems) and compared with the published sequence (M37154) using Mutation Surveyor software (SoftGenetics, Philadelphia, PA, USA). Mutation testing was performed on parental samples and microsatellite analysis of six markers on chromosome 20 was undertaken to confirm family relationships when a novel de novo mutation was identified (primers available on request).
###end p 20
###begin p 21
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT4</italic>
When no GLUD1 mutation was identified, exons 1-3 of the SIRT4 gene were analysed. All exons were amplified by PCR using a single set of primers with the exception of exon 1, which was amplified in two overlapping fragments (for primer sequences see Supplementary Table 1). PCR products were sequenced and compared with the published sequence () using Mutation Surveyor software (SoftGenetics).
###end p 21
###begin title 22
Functional analysis of GDH activity
###end title 22
###begin p 23
###xml 421 426 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 428 431 421 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">(8)</xref>
###xml 487 492 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 494 497 487 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">(9)</xref>
###xml 55 62 <span type="species:ncbi:9606">patient</span>
###xml 114 132 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Lymphocytes were isolated from peripheral blood of the patient with the novel P436L mutation and transformed with Epstein-Barr virus to establish lymphoblast cultures. The activity of GDH in lymphoblast homogenates and the effect of added GTP were determined spectrophotometrically by the oxidation of NADH at 25 degreesC in Tris-0.01 M acetate buffer, pH 8, containing 10 muM EDTA according to the protocol of de Lonlay et al. (8). Protein was measured according to the method of Lowry et al. (9).
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
Molecular genetics
###end title 25
###begin p 26
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 117 124 117 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 395 402 <span type="species:ncbi:9606">patient</span>
Seven different heterozygous mutations in the GLUD1 gene were identified in 13 out of 17 screened probands (76%; see Table 1). Three mutations were novel: N410D, D451V and P436L. These mutations were not present in the probands' unaffected parents and affected residues were conserved across species. Mutations at residue N410 have previously been reported in patients with HI/HA, including one patient within this cohort, suggesting that N410 is a functionally important residue.
###end p 26
###begin p 27
###xml 211 218 211 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 253 260 <span type="species:ncbi:9606">patient</span>
###xml 394 401 <span type="species:ncbi:9606">patient</span>
Two mutations, S445L and R269H, were each identified in three unrelated families. All other mutations were identified in a single proband. Testing of unaffected parents demonstrated that the mutation had arisen de novo in 11 out of 13 probands. For one patient, with a S445L mutation, a spontaneous mutation could not be confirmed as DNA was unavailable from the unaffected father. In a second patient, the R269H mutation was inherited by the proband from their affected mother. Testing of further family members demonstrated that the R269H mutation was also present in the proband's maternal uncle and grandmother, all of whom have HI/HA.
###end p 27
###begin p 28
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT4</italic>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
Sequencing of SIRT4 in the four patients referred with HI/HA and negative for a GLUD1 mutation did not reveal any mutations. The mean serum ammonia concentration of this group of patients was 66.7 mumol/l (50-87 mumol/l). All four patients had diazoxide-responsive HI with no clinical symptoms suggestive of protein/leucine sensitivity.
###end p 28
###begin title 29
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients with GLUD1 mutation
###end title 29
###begin p 30
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 88 95 88 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 399 402 399 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATP</sub>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 603 611 <span type="species:ncbi:9606">patients</span>
The clinical characteristics of the 16 patients with a GLUD1 mutation are summarised in Table 1. The mean birth weight of our cohort with a mutation was 3133 g at a mean gestational age of 38.6 weeks. Macrosomia was not a common feature with birth weight >90th centile in only three patients. The age of presentation was delayed (mean of 23.4 weeks) in comparison with the patients with CHI due to KATP channel mutations, with only three presenting in the neonatal period. Two patients were successfully managed with manipulation of diet alone; all others required treatment with diazoxide. None of our patients required a pancreatectomy.
###end p 30
###begin p 31
###xml 710 711 708 709 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 737 741 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">(10)</xref>
###xml 1186 1191 1184 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 12 presented at 1 year of age with a tonic-clonic seizure associated with HI (insulin 9.6 mU/l and blood glucose 1.7 mmol/l). She had a normal serum ammonia concentration (21 mumol/l) on presentation and on repeated measurements (30 and 41 mumol/l) during childhood. She responded to diazoxide and demonstrated a normal fasting tolerance on a moderate dose of diazoxide (12-15 mg/kg per day). However, she continued to experience intermittent hypoglycaemic episodes in the postprandial period even on a high dose of diazoxide (15-17 mg/kg per day). She was hence evaluated for leucine sensitivity at 13 years of age by an oral leucine tolerance test. Following a fast of 4 h, an oral dose of 0.15 g/kg l-leucine was administered (10). Blood glucose and plasma insulin levels were then measured at -30, 0, 30, 60, 90 and 120 min. Diazoxide was not discontinued for the purpose of the test. The test was stopped at 60 min following the oral leucine load as she developed symptomatic (sweating, disordered consciousness and blurred vision) hypoglycaemia with a blood glucose concentration of 2.2 mmol/l and simultaneous plasma insulin concentration of 69.5 mU/l. Sequencing of the GLUD1 gene was requested in view of the severe leucine sensitivity. At the age of 13.7 years, she has mild learning difficulties with memory skills and emotional functioning being the areas of most concern.
###end p 31
###begin p 32
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
There was a high incidence of seizures in our cohort of patients with a GLUD1 mutation. Out of 16 patients, 15 presented with seizures and 7 (43%) of them have developed epilepsy. All of the patients who developed epilepsy had generalised seizures. Out of seven patients with epilepsy, six had mutations in exons 6 and 7. All three patients with the mutation S445L developed epilepsy.
###end p 32
###begin title 33
GDH activity in lymphoblasts
###end title 33
###begin p 34
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 65 72 <span type="species:ncbi:9606">patient</span>
The activity and allosteric response of GDH in lymphoblasts from patient 12 were measured. She had normal basal GDH activities, but the half-maximal inhibitory concentration of GTP expressed in nmol/l (IC50) was 470% higher than that of controls (n=20) consistent with an excessive activity of GDH.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 210 220 210 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4 bib5 bib11">(4, 5, 11)</xref>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
The phenotype of CHI due to mutations in the GLUD1 gene is well characterised. It is reported to be milder, not usually associated with macrosomia at birth and tends to escape recognition till later in infancy (4, 5, 11). This was confirmed in our study where the mean age of presentation was 23.4 weeks with only 3 out of 17 patients presenting in the neonatal period. Interestingly, only three patients had a birth weight of >90th centile and all three had the S445L mutation. This may indicate that this mutation causes more severe foetal HI than the other mutations identified in our cohort.
###end p 36
###begin p 37
###xml 73 81 73 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12 bib13">(12, 13)</xref>
###xml 368 372 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">(13)</xref>
###xml 468 473 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 650 655 646 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 657 661 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">(14)</xref>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
Epilepsy has been frequently reported in association with HI/HA syndrome (12, 13). The increased frequency of epilepsy is thought to be either the result of a) hypoglycaemic brain injury due to recurrent hypoglycaemia or b) chronic HA or c) decreased concentrations of glutamine and the neurotransmitter gamma-aminobutyric acid in the brain due to raised GDH activity (13). Our study confirms that a high risk of epilepsy is associated with HI due to mutations in the GLUD1 gene, as 7 out of 16 (43%) of our patients developed epilepsy. Six out of the seven patients had mutations in exons 6 and 7; this was consistent with the study by Bahi-Buisson et al. (14), which reported that epilepsy is associated more frequently with mutations in exons 6 and 7. The mechanism of this genotype-phenotype association according to the location of the mutations is as yet unclear.
###end p 37
###begin p 38
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 175 185 175 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4 bib8 bib15">(4, 8, 15)</xref>
###xml 402 403 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">(16)</xref>
###xml 616 617 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 652 653 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 671 679 671 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17 bib18">(17, 18)</xref>
###xml 787 792 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 858 862 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">(19)</xref>
###xml 1461 1466 1459 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 720 728 <span type="species:ncbi:9606">patients</span>
###xml 868 875 <span type="species:ncbi:9606">patient</span>
###xml 1111 1118 <span type="species:ncbi:9606">patient</span>
###xml 1425 1433 <span type="species:ncbi:9606">patients</span>
The most consistent feature of the HI due to mutations in GLUD1 is the persistent HA, and hence the term 'HI/HA syndrome' is used synonymously with CHI due to GLUD1 mutations (4, 8, 15). It is proposed that HA is the result of excessive GDH activity in the hepatocytes leading to an increase in the production of ammonia from glutamate and/or depletion of glutamate with reduction in the production of N-acetylglutamate, an allosteric activator essential for the first step of ammonia detoxification (16). The second mechanism is supported by the reduction in the concentration of blood ammonia on administration of N-carbamylglutamate (an analogue of N-acetylglutamate) (17, 18). There has been one other report of two patients (father and son) with HI due to the R269H mutation in the GLUD1 gene and normal serum ammonia concentrations (35 and 28 mumol/l) (19). Our patient with the novel P436L mutation had a completely normal serum ammonia concentration (highest being 41 mumol/l) that led to a delay in establishing the molecular diagnosis. If the origin of the HA is in the liver, it is possible that our patient is mosaic for the mutation with the mutation being absent or at <50% in the hepatic tissues. And hence this absence of HA may not be genotype specific. However, we cannot prove or disprove this possibility without a liver/pancreatic biopsy. Similarly, mosaicism may be the underlying mechanism in our four patients with HI/HA syndrome and no GLUD1 mutation with the mutation affecting the liver and pancreas, but not blood.
###end p 38
###begin p 39
###xml 568 573 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 53 60 <span type="species:ncbi:9606">patient</span>
###xml 407 414 <span type="species:ncbi:9606">patient</span>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
Enzymatic analysis of the lymphoblastic GDH from our patient with the P436L mutation showed a loss of GTP inhibition with the half-maximal inhibitory concentration of GTP being 470% higher than that of controls. Loss of GTP inhibition is known to increase glutamate oxidation in the presence of leucine causing leucine-sensitive HI, a classical feature of HI/HA syndrome. This was clinically evident in our patient with this novel P436L mutation and was confirmed by the oral leucine tolerance test. The confirmation of leucine sensitivity prompted us to sequence the GLUD1 gene and led to the molecular diagnosis. This suggests that analysis of the GLUD1 gene must be considered in all patients with leucine sensitivity even in the absence of HA.
###end p 39
###begin p 40
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">(20)</xref>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
This study also reports two other novel mutations (N410D and D451V) in the GLUD1 gene. N410 is located in the antenna-like structure connecting to the pivot helix of the GDH structure. A mutation (N410T) previously described at the same residue is known to cause HI/HA (20). D451 is located in the allosteric domain of the GLUD1 gene, a common site for mutations causing HI/HA syndrome and hence likely to be pathogenic by interfering with the allosteric binding sites. Conservation data suggest that these residues are functionally important as they are both well conserved among species.
###end p 40
###begin p 41
###xml 85 88 85 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">(6)</xref>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sirt4</italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT4</italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 105 109 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 217 221 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 276 280 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 458 466 <span type="species:ncbi:9606">patients</span>
SIRT4 has been shown to regulate insulin secretion by repressing the activity of GDH (6). Sirt4 knockout mice have increased glucose-stimulated and amino acid-stimulated insulin secretion in comparison with wild-type mice along with fasting hypoglycaemia in the male knockout mice. We hypothesised that a loss of function mutation of SIRT4 will cause a phenotype similar to gain of function GLUD1 mutations, i.e. HI/HA syndrome. However, our cohort of HI/HA patients with no known genetic aetiology is small, and hence the negative findings of our study are not enough to exclude a putative role of this gene in HI/HA syndrome.
###end p 41
###begin title 42
Conclusion
###end title 42
###begin p 43
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Mutations in the GLUD1 gene are not always associated with HA; hence mutational analysis of the GLUD1 gene may be indicated in patients with HI with evidence of leucine sensitivity even in the absence of HA. GLUD1 gene mutations cause a mild form of CHI associated with normal birth weight, delayed age at presentation and a high risk of epilepsy.
###end p 43
###begin title 44
Declaration of interest
###end title 44
###begin p 45
The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.
###end p 45
###begin title 46
Funding
###end title 46
###begin p 47
This work was funded by the Wellcome Trust (081188/A/06/Z).
###end p 47
###begin title 48
Acknowledgements
###end title 48
###begin p 49
###xml 554 562 <span type="species:ncbi:9606">Children</span>
The authors would like to thank Michael Day and Kevin Colclough for their technical assistance. This study was funded by the Wellcome Trust (081188/A/06/Z). S E Flanagan is the Sir Graham Wilkins Peninsula Medical School Research Fellow and S Ellard was funded by the Royal Devon and Exeter NHS Foundation Trust Research and Development Directorate. The authors would also like to thank the clinicians who provided clinical information, including Dr Ariane Spitaels from Department of Paediatric and Adolescent Endocrinology, Groote Schuur and Red Cross Children's Hospitals, University of Cape Town, Cape Town, South Africa.
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
###xml 38 45 <span type="species:ncbi:9606">infants</span>
Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene
###end article-title 51
###begin article-title 52
###xml 0 1 0 1 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
l-glutamate dehydrogenases: distribution, properties and mechanism
###end article-title 52
###begin article-title 53
Regulation of insulin release by factors that also modify glutamate dehydrogenase
###end article-title 53
###begin article-title 54
Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene
###end article-title 54
###begin article-title 55
###xml 46 54 <span type="species:ncbi:9606">children</span>
Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome
###end article-title 55
###begin article-title 56
SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells
###end article-title 56
###begin article-title 57
Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase
###end article-title 57
###begin article-title 58
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients
###end article-title 58
###begin article-title 59
Protein measurement with the Folin phenol reagent
###end article-title 59
###begin article-title 60
###xml 50 51 50 51 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 63 71 <span type="species:ncbi:9606">children</span>
Serum-insulin changes following administration of l-leucine to children
###end article-title 60
###begin article-title 61
Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases
###end article-title 61
###begin article-title 62
Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations
###end article-title 62
###begin article-title 63
Myoclonic absence epilepsy with photosensitivity and a gain of function mutation in glutamate dehydrogenase
###end article-title 63
###begin article-title 64
Neurological aspects of hyperinsulinism-hyperammonaemia syndrome
###end article-title 64
###begin article-title 65
Novel missense mutations in the glutamate dehydrogenase gene in the congenital hyperinsulinism-hyperammonemia syndrome
###end article-title 65
###begin article-title 66
Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism
###end article-title 66
###begin article-title 67
Functional hyperactivity of hepatic glutamate dehydrogenase as a cause of the hyperinsulinism/hyperammonemia syndrome: effect of treatment
###end article-title 67
###begin article-title 68
###xml 28 35 <span type="species:ncbi:9606">patient</span>
Biochemical evaluation of a patient with a familial form of leucine-sensitive hypoglycemia and concomitant hyperammonemia
###end article-title 68
###begin article-title 69
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Novel missense mutations outside the allosteric domain of glutamate dehydrogenase are prevalent in European patients with the congenital hyperinsulinism-hyperammonemia syndrome
###end article-title 69
###begin article-title 70
Hyperinsulinism-hyperammonemia syndrome caused by mutant glutamate dehydrogenase accompanied by novel enzyme kinetics
###end article-title 70
###begin p 71
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUD1</italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Summary of the clinical characteristics of patients with a mutation in the GLUD1 gene.
###end p 71

